# Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

> **NCT01392547** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 72 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** vatreptacog alfa (activated)
- **DRUG:** eptacog alfa (activated)

## Key facts

- **NCT ID:** NCT01392547
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392547, "Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01392547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*